Mechanism of action, resistance, synergism, and clinical implications of azithromycin. 2022

Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran.

BACKGROUND Azithromycin (AZM), sold under the name Zithromax, is classified as a macrolide. It has many benefits due to its immunomodulatory, anti-inflammatory, and antibacterial effects. This review aims to study different clinical and biochemisterial aspects and properties of this drug which has a priority based on literature published worldwide. METHODS Several databases including Web of Science, Google Scholar, PubMed, and Scopus were searched to obtain the relevant studies. RESULTS AZM mechanism of action including the inhibition of bacterial protein synthesis, inhibition of proinflammatory cytokine production, inhibition of neutrophil infestation, and macrophage polarization alteration, gives it the ability to act against a wide range of microorganisms. Resistant organisms are spreading and being developed because of the irrational use of the drug in the case of dose and duration. AZM shows synergistic effects with other drugs against a variety of organisms. This macrolide is considered a valuable antimicrobial agent because of its use as a treatment for a vast range of diseases such as asthma, bronchiolitis, COPD, cystic fibrosis, enteric infections, STIs, and periodontal infections. CONCLUSIONS Our study shows an increasing global prevalence of AZM resistance. Thus, synergistic combinations are recommended to treat different pathogens. Moreover, continuous monitoring of AZM resistance by registry centers and the development of more rapid diagnostic assays are urgently needed.

UI MeSH Term Description Entries
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D017963 Azithromycin A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. Azadose,Azithromycin Dihydrate,Azithromycin Monohydrate,Azitrocin,Azythromycin,CP-62993,Goxal,Sumamed,Toraseptol,Ultreon,Vinzam,Zentavion,Zithromax,Zitromax,CP 62993,CP62993,Dihydrate, Azithromycin,Monohydrate, Azithromycin

Related Publications

Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
January 2021, Frontiers in microbiology,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
January 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
January 2007, Neurourology and urodynamics,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
November 2020, Journal of fungi (Basel, Switzerland),
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
January 2006, Human reproduction update,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
December 1975, Lijecnicki vjesnik,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
December 2019, Antimicrobial agents and chemotherapy,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
March 1971, Journal of bacteriology,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
April 1992, Seminars in oncology,
Mohsen Heidary, and Ahmad Ebrahimi Samangani, and Abolfazl Kargari, and Aliakbar Kiani Nejad, and Ilya Yashmi, and Moloudsadat Motahar, and Elahe Taki, and Saeed Khoshnood
May 1994, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!